105 related articles for article (PubMed ID: 23875616)
1. Co-encapsulation of human serum albumin and superparamagnetic iron oxide in PLGA nanoparticles: part I. Effect of process variables on the mean size.
Shubhra QT; Kardos AF; Feczkó T; Mackova H; Horák D; Tóth J; Dósa G; Gyenis J
J Microencapsul; 2014; 31(2):147-55. PubMed ID: 23875616
[TBL] [Abstract][Full Text] [Related]
2. Co-encapsulation of human serum albumin and superparamagnetic iron oxide in PLGA nanoparticles: part II. Effect of process variables on protein model drug encapsulation efficiency.
Shubhra QT; Feczkó T; Kardos AF; Tóth J; Mackova H; Horak D; Dósa G; Gyenis J
J Microencapsul; 2014; 31(2):156-65. PubMed ID: 23875617
[TBL] [Abstract][Full Text] [Related]
3. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization.
Cun D; Jensen DK; Maltesen MJ; Bunker M; Whiteside P; Scurr D; Foged C; Nielsen HM
Eur J Pharm Biopharm; 2011 Jan; 77(1):26-35. PubMed ID: 21093589
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of superparamagnetic iron oxide/doxorubicin co-loaded poly (lactic-co-glycolic acid) nanospheres prepared by different emulsion solvent evaporation methods.
Mosafer J; Teymouri M
Artif Cells Nanomed Biotechnol; 2018 Sep; 46(6):1146-1155. PubMed ID: 28789586
[TBL] [Abstract][Full Text] [Related]
5. Mixture designs in the optimisation of PLGA nanoparticles: influence of organic phase composition on β-aescin encapsulation.
Ven HV; Vandervoort J; Weyenberg W; Apers S; Ludwig A
J Microencapsul; 2012; 29(2):115-25. PubMed ID: 22047548
[TBL] [Abstract][Full Text] [Related]
6. Ultrafine PEG-coated poly(lactic-co-glycolic acid) nanoparticles formulated by hydrophobic surfactant-assisted one-pot synthesis for biomedical applications.
Chu CH; Wang YC; Huang HY; Wu LC; Yang CS
Nanotechnology; 2011 May; 22(18):185601. PubMed ID: 21415469
[TBL] [Abstract][Full Text] [Related]
7. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution.
Mainardes RM; Evangelista RC
Int J Pharm; 2005 Feb; 290(1-2):137-44. PubMed ID: 15664139
[TBL] [Abstract][Full Text] [Related]
8. Preparation and characterization of poly(DL-lactide-co-glycolide) nanoparticles for siRNA delivery.
Cun D; Foged C; Yang M; Frøkjaer S; Nielsen HM
Int J Pharm; 2010 May; 390(1):70-5. PubMed ID: 19836438
[TBL] [Abstract][Full Text] [Related]
9. Effect of microfluidization parameters on the physical properties of PEG-PLGA nanoparticles prepared using high pressure microfluidization.
Sani SN; Das NG; Das SK
J Microencapsul; 2009 Sep; 26(6):556-61. PubMed ID: 18946802
[TBL] [Abstract][Full Text] [Related]
10. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
11. In vitro release characteristics and cellular uptake of poly(D,L-lactic-co-glycolic acid) nanoparticles for topical delivery of antisense oligodeoxynucleotides.
Chen YS; Alany RG; Young SA; Green CR; Rupenthal ID
Drug Deliv; 2011; 18(7):493-501. PubMed ID: 21696294
[TBL] [Abstract][Full Text] [Related]
12. Development and optimization of N-Acetylcysteine-loaded poly (lactic-co-glycolic acid) nanoparticles by electrospray.
Karimi Zarchi AA; Abbasi S; Faramarzi MA; Gilani K; Ghazi-Khansari M; Amani A
Int J Biol Macromol; 2015 Jan; 72():764-70. PubMed ID: 25224287
[TBL] [Abstract][Full Text] [Related]
13. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content.
Budhian A; Siegel SJ; Winey KI
Int J Pharm; 2007 May; 336(2):367-75. PubMed ID: 17207944
[TBL] [Abstract][Full Text] [Related]
14. Formulation of ciprofloxacin hydrochloride loaded biodegradable nanoparticles: optimization of technique and process variables.
Mobarak DH; Salah S; Elkheshen SA
Pharm Dev Technol; 2014 Nov; 19(7):891-900. PubMed ID: 24032531
[TBL] [Abstract][Full Text] [Related]
15. The effect of formulation variables on the characteristics of insulin-loaded poly(lactic-co-glycolic acid) microspheres prepared by a single phase oil in oil solvent evaporation method.
Hamishehkar H; Emami J; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Nokhodchi A
Colloids Surf B Biointerfaces; 2009 Nov; 74(1):340-9. PubMed ID: 19717287
[TBL] [Abstract][Full Text] [Related]
16. Optimization of iron oxide nanoparticles encapsulation within poly(d,l-lactide-co-glycolide) sub-micron particles.
Okassa LN; Marchais H; Douziech-Eyrolles L; Hervé K; Cohen-Jonathan S; Munnier E; Soucé M; Linassier C; Dubois P; Chourpa I
Eur J Pharm Biopharm; 2007 Aug; 67(1):31-8. PubMed ID: 17289360
[TBL] [Abstract][Full Text] [Related]
17. PLGA nanoparticles loaded with the antileishmanial saponin β-aescin: factor influence study and in vitro efficacy evaluation.
Van de Ven H; Vermeersch M; Matheeussen A; Vandervoort J; Weyenberg W; Apers S; Cos P; Maes L; Ludwig A
Int J Pharm; 2011 Nov; 420(1):122-32. PubMed ID: 21864661
[TBL] [Abstract][Full Text] [Related]
18. Optimization of PLGA nanoparticles formulation containing L-DOPA by applying the central composite design.
Zhou YZ; Alany RG; Chuang V; Wen J
Drug Dev Ind Pharm; 2013 Feb; 39(2):321-30. PubMed ID: 22607101
[TBL] [Abstract][Full Text] [Related]
19. Calcium phosphate embedded PLGA nanoparticles: a promising gene delivery vector with high gene loading and transfection efficiency.
Tang J; Chen JY; Liu J; Luo M; Wang YJ; Wei XW; Gao X; Wang BL; Liu YB; Yi T; Tong AP; Song XR; Xie YM; Zhao Y; Xiang M; Huang Y; Zheng Y
Int J Pharm; 2012 Jul; 431(1-2):210-21. PubMed ID: 22561795
[TBL] [Abstract][Full Text] [Related]
20. Optimization of polylactic-co-glycolic acid nanoparticles containing itraconazole using 2(3) factorial design.
Prakobvaitayakit M; Nimmannit U
AAPS PharmSciTech; 2003 Dec; 4(4):E71. PubMed ID: 15198566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
